Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus

Hanabusa, Tadashi; Kubo, Kazuki; Oki, Chikato; Nakano, Yoshio; Okai, Kazuhiko; Sanke, Tokio; Nanjo, Kishio

doi:10.1016/0168-8227(92)90073-z

Cited by 45 publications

(34 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, the ratio of circulating insulin to IAPP was reduced in type 2 diabetes. These findings are in accord with previous results that subjects with obesity, exhibiting low insulin sensitivity (18), have elevated IAPP levels (15,16) and increased IAPP secretion (33,34). Also, dexamethasoneinduced insulin resistance and streptozotocin-induced diabetes in rodents are accompanied by overexpression of IAPP vs insulin (18,19).…”

Section: Discussionsupporting

confidence: 82%

“…In the normal subjects, fasting circulating IAPP was approximately 4 pmol/l, which is in the range of 2-10 pmol/l found in previous studies in healthy subjects (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)21). Furthermore, in the normal subjects, there was a close correlation between circulating IAPP and circulating insulin in the fasting state, the regression coefficient being 0.74, which confirms previous studies (7,12,14).…”

Section: Discussionsupporting

confidence: 77%

“…IAPP is co-stored with insulin in the pancreatic B cells and previous studies have shown that IAPP and insulin are co-released under a variety of experimental conditions (7)(8)(9)(10)(11)(12)(13)(14)(15)(16). However, it has also been suggested that under certain conditions IAPP and insulin are released in a non-parallel fashion.…”

Section: Discussionmentioning

confidence: 93%

“…Previous studies have shown that in normal subjects, the peptide is released simultaneously with insulin in response to oral and intravenous glucose, ingestion of a mixed meal and intravenous arginine (7)(8)(9)(10)(11)(12)(13)(14). It has also been shown that in non-diabetic obese subjects, circulating IAPP levels are elevated and the IAPP response to glucose is exaggerated compared with non-obese subjects (15,16). This would suggest that increased secretion of IAPP evolves before the onset of type 2 diabetes, for example in the state of reduced insulin sensitivity which often accompanies obesity (17).…”

Section: Introductionmentioning

confidence: 93%

See 3 more Smart Citations

No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes

Åhrén

Gutniak²

1997

European Journal of Endocrinology

View full text Add to dashboard Cite

Objectives: To examine whether glucagon-like peptide-1 (GLP-1), which has been suggested as a new therapeutic agent in type 2 diabetes, affects circulating islet amyloid polypeptide (IAPP), a B-cell peptide of potential importance for diabetes pathophysiology. Design: GLP-1 was administered in a buccal tablet (400 mg) to seven healthy subjects and nine subjects with type 2 diabetes. Serum IAPP and insulin levels were measured before and after GLP-1 administration.Results: In the fasting state, serum IAPP was 4.1 Ϯ 0.3 pmol/l in the controls vs 9.8 Ϯ 0.9 pmol/l in the subjects with type 2 diabetes (P < 0.001). IAPP correlated with insulin only in controls (r=0.74, P ¼ 0.002) but not in type 2 diabetes (r ¼ 0.26, NS). At 15 min after GLP-1, circulating IAPP increased to 6.0Ϯ0.5 pmol/l in controls (P ¼ 0.009) and to 13.8Ϯ1.2 pmol/l in type 2 diabetes (P ¼ 0.021). In both groups, serum insulin increased and blood glucose decreased compared with placebo. In controls serum IAPP increased in parallel with insulin (r ¼ 0.79, P ¼ 0.032), whereas in type 2 diabetes the increase in IAPP did not correlate with the increase in insulin. Conclusion: Type 2 diabetes is associated with elevated circulating IAPP; GLP-1 stimulates IAPP secretion both in healthy human subjects and in type 2 diabetes; IAPP secretion correlates with insulin secretion only in healthy subjects and not in type 2 diabetes.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes

Åhrén

Gutniak²

1997

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Amylin Secretion in the Obese State. Although regulation of amylin secretion has not been extensively evaluated in humans, there is some evidence for elevation of amylin in the obese state (Ludvik et al, 1991;Enoki et al, 1992;Hanabusa et al, 1992; Amylin Blackard et al, 1994;Kautzky-Willer et al, 1994;Roth et al, 2010;Lee et al, 2011;Jacobsen et al, 2012). Plasma levels appear to reach up to approximately twice those achieved in nonobese subjects, but whether this results overall in sustained levels of amylin in excess of those that would be achieved postprandially is not clear.…”

Section: B Obesitymentioning

confidence: 99%